GI 111924

Drug Profile

GI 111924

Latest Information Update: 24 Aug 1999

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 24 Aug 1999 Discontinued-I for Prostate cancer in United Kingdom (Unknown route)
  • 08 Sep 1998 No-Development-Reported for Prostate cancer in United Kingdom (Unknown route)
  • 29 Aug 1996 Phase-I clinical trials for Prostate cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top